Inactive Instrument
InMed Pharmaceuticals Inc Stock Deutsche Boerse AG
Stocks
CA13764X1069
Biotechnology & Medical Research
|
End-of-day quote
Deutsche Boerse AG
|
||
| - EUR | - |
|
| 09-09 | InMed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2026 | CI |
| 09-08 | InMed Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt | CI |
| Market Cap | 8.84M 6.2M 5.51M 5.14M 4.69M 596M 8.92M 62.21M 24.11M 305M 23.27M 22.77M 978M | P/E 2025 |
-0.39x | P/E 2026 | -0.5x |
|---|---|---|---|---|---|
| Enterprise Value | 6.6M 4.63M 4.12M 3.84M 3.5M 445M 6.66M 46.48M 18.01M 228M 17.39M 17.01M 731M | EV / Sales 2025 |
-1,305,911x | EV / Sales 2026 | - |
| Free-Float |
99.94% | Yield 2025 * |
-
| Yield 2026 | - |
Last Transcript: InMed Pharmaceuticals Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Eric Adams
CEO | Chief Executive Officer | 63 | 2016-06-15 |
Netta Jagpal
DFI | Director of Finance/CFO | 53 | 2024-02-19 |
| Chief Operating Officer | 57 | 2022-07-14 |
| Director | Title | Age | Since |
|---|---|---|---|
Eric Adams
BRD | Director/Board Member | 63 | 2016-06-15 |
Andrew Hull
CHM | Chairman | 63 | 2022-11-30 |
Nicole Lemerond
BRD | Director/Board Member | 51 | 2022-08-07 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.16% | +3.04% | +49.37% | +94.17% | 74.16B | |
| -3.11% | -3.53% | +21.92% | +74.60% | 57.39B | |
| +0.89% | -0.63% | +4.28% | +34.51% | 47.64B | |
| +0.36% | +0.81% | +352.17% | +689.61% | 44.29B | |
| -0.96% | -4.50% | +26.36% | +33.18% | 42.5B | |
| -0.20% | -0.77% | +3.74% | +100.60% | 40.71B | |
| -0.54% | +2.93% | +9.31% | +50.41% | 30.97B | |
| -2.68% | +2.92% | +29.63% | +19.50% | 28.53B | |
| +0.05% | -1.64% | -7.28% | -14.06% | 24.34B | |
| Average | -0.23% | -0.59% | +54.39% | +120.28% | 43.39B | |
| Weighted average by Cap. | +0.12% | -0.84% | +58.77% | +129.91% |
| 2025 | 2026 | |
|---|---|---|
| Net sales | 4.94 3.47 3.08 2.88 2.62 333.31 4.99 34.8 13.48 170.39 13.02 12.74 546.86 | - |
| Net income | -8.16M -5.73M -5.09M -4.75M -4.33M -550M -8.24M -57.46M -22.27M -281M -21.5M -21.03M -903M | -12.56M -8.81M -7.83M -7.31M -6.66M -847M -12.68M -88.43M -34.27M -433M -33.08M -32.36M -1.39B |
| Net Debt | -10.38M -7.28M -6.47M -6.04M -5.5M -700M -10.47M -73.06M -28.31M -358M -27.33M -26.74M -1.15B | -2.23M -1.57M -1.39M -1.3M -1.18M -151M -2.25M -15.73M -6.09M -77.02M -5.88M -5.76M -247M |
Employees
-
Select your edition
All financial news and data tailored to specific country editions
